SR-18465 for Inhibition of MMP-13 in Multiple Myeloma


This patent-pending technology is a SR-18465 compound, which is an osteoclastogenesis matrix metalloproteinase 13 (MMP-13) highly specific inhibitor for the treatment of multiple myeloma. The compound specifically inhibits MMP-13 rather than the entire MMP family of endogenous proteins. SR-18465 directly impacts the viability of several multiple myeloma cell lines by up to 50% over 48 hours but had minimal effects on stromal cells of the bone microenvironment. Most significantly, in vivo SR-18465 significantly reduces the growth of multiple myeloma and, subsequently tumor burden.

Patent Information:
For Information, Contact:
Dana Vouglitois
Florida Atlantic University
Gregg Fields
Conor Lynch
© 2024. All Rights Reserved. Powered by Inteum